Holen Sie sich die Stockscreener-App
7.49
2.60%
0.19
Vorhandelsmarkt:
7.49
Schlusskurs vom Vortag:
$7.30
Offen:
$7.35
24-Stunden-Volumen:
1.20M
Relative Volume:
0.67
Marktkapitalisierung:
$483.63M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-3.963
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+8.24%
1M Leistung:
+24.01%
6M Leistung:
+386.36%
1J Leistung:
+256.67%
1-Tages-Spanne:
$7.20
$7.56
1-Wochen-Bereich:
$6.62
$7.56
52-Wochen-Spanne:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
7.49 | 471.36M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Eingeleitet | Leerink Partners | Outperform |
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com
Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com
How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com
Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com
Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com
Will Immuneering Corporation stock beat EPS estimatesPortfolio Gains Report & High Win Rate Trade Alerts - newser.com
Can machine learning forecast Immuneering Corporation recoveryMarket Volume Report & Entry Point Confirmation Signals - newser.com
Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com
Why Immuneering Corporation stock is recommended by analystsWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
Can momentum traders help lift Immuneering CorporationJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Immuneering Corp. Shines in Positive Earnings Call - TipRanks
What momentum indicators show for Immuneering Corporation stockWeekly Stock Report & High Return Trade Guides - newser.com
Immuneering rises after smaller-than-expected Q3 loss - TradingView
Immuneering Corp. Reports Strong Q3 2025 Progress - TipRanks
Earnings call transcript: Immuneering Q3 2025 emphasizes cash boost and trial progress - Investing.com Nigeria
Immuneering Corporation (IMRX) Q3 FY2025 earnings call transcript - Yahoo Finance
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - The Manila Times
Immuneering Corporation Reports 86% Overall Survival in Pancreatic Cancer Patients and Secures $225 Million in Financing - Quiver Quantitative
[8-K] Immuneering Corp Reports Material Event | IMRX SEC FilingForm 8-K - Stock Titan
What indicators show strength in Immuneering CorporationWeekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
A look into Immuneering Corp (IMRX)’s deeper side - Setenews
A Preview Of Immuneering's Earnings - Benzinga
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):